References
- BrusascoV. Reducing cholinergic constriction: the major reversible mechanism in COPD. Eur Respir Rev 2006; 15 32–36.
- Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2014. Available from: < http://www.goldcopd.org/>[ accessed July 31 2014].
- SinghD, BrooksJ, HaganG, et al. Superiority of “triple” therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD. Thorax 2008; 63:592–598.
- CazzolaM, AndoF, SantusP, et al. A pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the airflow obstruction of patients with severe-to-very severe COPD. Pulm Pharmacol Ther 2007; 20:556–561.
- HananiaNA, CraterGD, MorrisAN, et al. Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD. Respir Med 2012; 106:91–101.
- GSK. Prescribing Information for ADVAIR DISKUS. Available from: < https://www.gsksource.com/gskprm/htdocs/documents/ADVAIR-DISKUS-PI-MG.PDF >.
- GSK. Prescribing information for INCRUSE™ ELLIPTA®. Available from: < https://www.gsksource.com/gskprm/htdocs/documents/INCRUSE-ELLIPTA-PI-PIL.PDF>[ accessed December 2014].
- GSK. Summary of product characteristics for INCRUSE™ ELLIPTA®. Available from: <http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002809/WC500167430.pdf> [accessed September 15 2015].
- DonohueJF, AnzuetoA, BrooksJ, et al. A randomized, double-blind dose-ranging study of the novel LAMA GSK573719 in patients with COPD. Respir Med 2012; 106:970–979.
- ChurchA, BeeraheeM, BrooksJ, MehtaR, ShahP. Dose response of umeclidinium administered once or twice daily in patients with COPD: a randomised cross-over study. BMC Pulm Med 2014; 14:2.
- CelliBR, MacNeeW. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23:932–946.
- HankinsonJL, KawutSM, ShaharE, et al. Performance of American Thoracic Society-recommended spirometry reference values in a multiethnic sample of adults: the multi-ethnic study of atherosclerosis (MESA) lung study. Chest 2010; 137:138–145.
- HankinsonJL, OdencrantzJR, FedanKB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 1999; 159:179–187.
- ManaliED, LyberopoulosP, TriantafillidouC, et al. MRC chronic Dyspnea Scale: Relationships with cardiopulmonary exercise testing and 6-minute walk test in idiopathic pulmonary fibrosis patients: a prospective study. BMC Pulm Med 2010; 10:32.
- World Medical Association. WMA Declaration of Helsinki - ethical principles for medical research involving human subjects. Available from: http://www.wma.net/en/30publications/10policies/b3/index.html.
- DonohueJF. Minimal clinically important differences in COPD lung function. COPD 2005; 2:111–124.
- JonesPW. St. George's Respiratory Questionnaire: MCID. COPD 2005; 2:75–79.
- Siddiqui O, Hung HM, O'Neill R. MMRM vs. LOCF: a comprehensive comparison based on simulation study and 25 NDA datasets. J Biopharm Stat 2009; 19:227–246.
- DecramerM, AnzuetoA, KerwinE, et al. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials. Lancet Respir Med 2014; 2:472–486.
- Donohue J, Kalberg C, Shah P, et al. Dose response of umeclidinium administered once or twice daily in patients with COPD: pooled analysis of two randomized, double-blind, placebo-controlled studies. J Clin Pharmacol 2014; 54:1214–1220.
- TrivediR, RichardN, MehtaR, ChruchA. Umeclidinium in patients with COPD: a randomised, placebo-controlled study. Eur Respir J 2014; 43:72–81.
- Jung KS, Park HY, Park SY, et al. Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study. Respir Med 2012; 106:382–389.
- AaronSD, VandemheenKL, FergussonD, et al. Tiotropium in combination with placeo, salmeterol or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2007; 146:545–555.
- WelteT, MiravitllesM, HernandezP, et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstractive pulmonary disease. Am J Respir Crit Care Med 2009; 180:741–750.
- ShortPM, WilliamsonPA, ElderDH, et al. The impact of tiotropium on mortality and exacerbations when added to inhhaled corticosteroids and long-acting β-agonist therapy in COPD. Chest 2012; 141:81–86.
- Balorira VillarA, PomboC. [Bronchodilator efficacy of combined salmeterol and tiotropium in patients with chronic obstructive pulmonary disease]. Arch Bronconeumol 2005; 41:130–134.
- Kon SSC, CanavanJL, JonesSE, et al. Minimum clinically important difference for the COPD Assessment Test: a prospective analysis. Lancet Respir Med 2014; 2:195–203.